Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis
Although biologics have revolutionized psoriasis treatment, they pose a significant burden on the healthcare budget. With the wide range of biologics available and the increasing number of biosimilars, insights into the real-world cost per responder (CPR) are required. Therefore, this study aims to evaluate the real-world CPR of adalimumab, ustekinumab, IL17-and IL23-inhibitors, incorporating both
